TABLE 2.
Overview of surgery and perioperative therapy.
| Perioperative therapy | PRE (n = 120) | PANDEMIC (n = 384) | p‐value c |
|---|---|---|---|
| Surgery, n (%) a | |||
| Bp/Bt | 35 (29)/84 (71) | 127 (35)/232 (65) | 0.23 |
| Ax/no Ax | 73 (61)/46 (39) | 186 (52)/174 (48) | 0.07 |
| Radiotherapy, n (%) | 0.24 | ||
| Yes/No | 94 (79)/25 (21) | 262(75)/89 (25) | |
| Chemotherapy, n (%) b | |||
| NAC/Adj | 65 (54)/55 (46) | 202 (53)/182 (47) | 0.77 |
| AC/ddAC/TC | 101 (84)/0 (0)/19 (16) | 246 (64)/54 (14)/84 (22) | <0.001 |
| wPTX/DTX | 31 (26)/69 (58) | 111 (29)/181 (47) | 0.21 |
Abbreviations: AC, doxorubicin + cyclophosphamide; Adj, adjuvant chemotherapy; Ax, axillary lymph node dissection; Bp, breast partial resection; Bt, breast total resection; DTX, tri‐weekly docetaxel; NAC, neoadjuvant chemotherapy; TC, docetaxel + cyclophosphamide; wPTX, weekly paclitaxel.
One patient in the PRE group died, and 24 patients of the PANDEMIC group did not undergo surgery for the following reasons: 11 patients were awaiting surgery at data cutoff, 8 patients participated in a clinical trial to omit surgery, 2 patients had distant metastases, and 1 each died, refused surgery, and canceled surgery because of another emerging cancer. One patient underwent axillary dissection only and no mastectomy.
Patients who changed to taxane during the course of the study were excluded.
Chi‐square test.